Mecain

Mepivacaine, the active ingredient in Mecain, is a local anesthetic presented as a sterile solution for epidural, infiltration, and intradermal use. It provides reversible nerve block for minor surgical and dental procedures, as well as epidural analgesia, in adult patients.

GNH USA supplies Mecain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global distribution.

Mepivacaine is used as a local anesthetic for procedures requiring regional nerve blockade.

- Dental procedures: provides rapid onset local anesthesia for extractions, restorations and minor oral surgery. - Minor surgical procedures: enables infiltration anesthesia for skin, soft‑tissue and superficial orthopedic interventions. - Epidural analgesia: offers regional pain control during labor, obstetric procedures and postoperative recovery.

Mepivacaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Transient tingling or numbness at the injection site. - Mild dizziness or light‑headedness. - Nausea or mild vomiting.

Serious or Rare Side Effects: - Allergic reactions such as rash, itching or anaphylaxis. - Cardiovascular collapse or severe hypotension. - Seizures or convulsions.

When using Mepivacaine, clinicians should observe several safety measures to minimise risk.

- Patient assessment: evaluate medical history for cardiac disease, epilepsy or hypersensitivity. - Dose limitation: adhere to recommended maximum dose based on body weight. - Monitoring: observe vital signs and neurologic status during and after administration. - Drug interactions: avoid concurrent use with other potent local anesthetics or class I antiarrhythmics. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at room temperature: keep in original container, protect from light and moisture.

Mepivacaine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Other local anesthetics: risk of cumulative toxicity. - Monoamine oxidase inhibitors (MAOIs): potential for severe hypertension.

Moderate Interactions (Monitor Closely): - Beta‑adrenergic blockers: may mask tachycardia signs of toxicity. - Calcium channel blockers: can potentiate hypotensive effects. - Diuretics: may reduce plasma protein binding, increasing free drug levels.